PET/CT in Ankara: Preparation, Costs and Results

PET assesses selected biological processes while CT depicts anatomy. Combining them may answer specific clinical questions.

PET alone is functional imaging. PET/CT adds CT anatomy to help localize the PET findings.

No. PET/CT may assess suspected disease, stage cancer, monitor therapy or investigate some noncancer conditions. It does not diagnose cancer by itself.

It may be used for lung cancer, lymphoma, head and neck, colorectal and selected other cancers, depending on the precise indication.

No. Very small lesions, certain less FDG-avid tumors and normal tracer uptake in some organs can limit detection.

No. Inflammation and infection can also show tracer uptake. Tissue sampling and pathology may be needed.

F-18 FDG is a radioactive glucose-like tracer used to evaluate metabolic activity. It is not the same as CT contrast dye.

PSMA PET uses a PSMA-targeted tracer for selected prostate cancer indications, whereas FDG evaluates glucose-related activity. They are not interchangeable.

Somatostatin-receptor tracers can help assess selected neuroendocrine tumors; availability and suitability vary.

Scanning may take roughly 20–45 minutes, with uptake time and preparation making the full visit several hours in some protocols.

FDG protocols commonly require approximately 4–6 hours of fasting, usually with plain water allowed. Preparation differs for other tracers.

Plain water is often encouraged for FDG imaging while caloric drinks are avoided. Ask your team if you are on fluid restrictions.

Requirements differ by study; confirm what beverages are permitted rather than assuming tea or coffee is acceptable.

Strenuous exercise can increase muscular FDG uptake; many protocols advise avoiding it for about 24 hours beforehand.

Yes, but glucose, insulin and meal timing need careful planning. Never change diabetes medicines without personalized instructions.

There is no universal single cut-off for all patients. Blood glucose is checked; ACR guidance calls for physician assessment when glucose is above 200 mg/dL.

Yes. PET uses a radioactive tracer and CT uses ionizing X-rays; benefits and risks are balanced for the clinical indication.

Appropriately indicated PET/CT is generally performed with acceptable risk, but radiation, IV injections and any CT contrast warrant individual assessment.

PET requires a radiotracer; the CT portion may or may not use separate intravenous iodinated contrast.

The scan itself is usually painless, although the injection and remaining still may be uncomfortable.

Always report pregnancy or possible pregnancy. Clinicians assess urgency, radiation risks and possible alternatives.

Tell the team if breastfeeding. Feeding or close-contact precautions depend on the radiotracer and site instructions.

Prolonged close contact may be limited for a few hours depending on tracer, activity and facility policy; a blanket 24-hour rule is not universal.

Patients are often encouraged to hydrate and urinate frequently unless fluid-restricted or otherwise instructed.

Most people may resume eating after the exam unless sedation or other instructions apply. People with diabetes should confirm their regimen.

Driving is generally possible without sedation. Do not drive if you received a sedative; arrange an escort.

Reporting times depend on complexity and workload. Confirm the expected turnaround with the provider; a fixed time cannot be guaranteed.

SUVmax is a standardized measure of peak tracer uptake in a region. It does not by itself confirm cancer or stage.

No. Infection, inflammation, normal physiologic activity and healing can also cause FDG uptake.

No. Small lesions or low-uptake tumors can be missed; a negative scan is interpreted with clinical and other findings.

PET/CT can aid assessment of nodal and distant spread in selected cancers; staging pathways differ by tumor.

It may help identify suspected metastases, but not perfectly; additional imaging or sampling may be necessary.

Timing varies by cancer, treatment and clinical objective; the oncology and nuclear medicine teams should select the interval.

CT shows anatomy; PET adds functional information from a radiotracer. PET/CT does not replace every diagnostic CT.

MRI uses magnetic fields without ionizing radiation; PET/CT uses radiotracer and CT X-rays. They address different clinical questions.

PET/MRI combines PET with MRI rather than CT; study duration, availability, detail and radiation profiles differ.

Often not. Imaging can identify suspicious sites, but tissue may still be needed for histology and biomarkers.

Routine yearly PET/CT for asymptomatic people is not generally recommended because of radiation and false positives.

Price varies with tracer, scanning range, CT protocol, reporting and coverage. Obtain a verified quote for the full examination.

Coverage depends on indication, authorized facility, authorization and up-to-date policy or payer rules.

PET/CT is performed at appropriately authorized nuclear medicine facilities. Confirm the actual site, tracer and appointment availability with Anka Sağlık Hizmetleri.

Before traveling from nearby provinces, confirm fasting, diabetes instructions, transport, escort and report delivery.

No. Coverage depends on indication and protocol, ranging from defined regions to wider-body imaging.

A qualified nuclear medicine physician and relevant imaging specialists interpret it; treatment decisions involve the referring team.

Yes. Infection, inflammation and healing after procedures may increase uptake. Report recent operations and treatments.